-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tusamitamab Ravtansine in Metastatic Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tusamitamab Ravtansine in Metastatic Breast Cancer Drug Details: Tusamitamab ravtansine is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – M-528101 in Postherpetic Neuralgia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - M-528101 in Postherpetic Neuralgia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. M-528101 in Postherpetic Neuralgia Drug Details: M-528101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexasertib Mesylate Monohydrate in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Prexasertib Mesylate Monohydrate in Bladder Cancer Drug Details: Prexasertib (LY-2606368 monomesylate monohydrate) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prexasertib Mesylate Monohydrate in Metastatic Transitional (Urothelial) Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Prexasertib Mesylate Monohydrate in Metastatic Transitional (Urothelial) Tract Cancer Drug Details: Prexasertib (LY-2606368 monomesylate monohydrate)...
-
Product Insights
Medulloblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Medulloblastoma Pipeline Drugs Market Report Overview Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of the brain located at the base of the skull, just above the brainstem. Symptoms associated with a Medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options...
-
Product Insights
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections. The Bladder Cancer pipeline market research report provides comprehensive...
-
Product Insights
Endometrial Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape. Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the...